V Lingareddy1, N R Ahmad, M Mohiuddin. 1. Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Abstract
PURPOSE: The purpose of this study was to analyze the efficacy and acute and late toxicity of reirradiation for recurrent rectal cancer. METHODS AND MATERIALS: Fifty-two patients with recurrent rectal adenocarcinoma following previous pelvic RT underwent reirradiation. Median initial RT dose to the pelvis was 50.4 Gy. Median reirradiation dose was 30.6 Gy. Twenty-two patients received 1.2 Gy b.i.d., and 30 patients received 1.8-2.0 Gy daily. Total cumulative doses ranged from 66.6 to 104.9 Gy (median: 84.4 Gy). Forty-seven patients (90%) received concurrent 5-FU chemotherapy. Forty-four patients were followed until death, and the median follow-up time was 16 months. RESULTS: The RTOG Grade 3 acute toxicity rate was 31%. The RTOG Grade 3 and 4 late toxicity rates were 23 and 10%, respectively. On multivariate analysis, the only factor associated with reduced late toxicity was hyperfractionated delivery of reirradiation. Bleeding, pain, and mass effect were palliated completely in 100, 65, and 24% of instances, respectively, and the majority of responding patients were palliated until death. The overall median survival time from retreatment was 12 months. The 2- and 3-year overall actuarial survival rates were 25 and 14%, respectively. CONCLUSION: This unique institutional approach to recurrent rectal cancers resulted in excellent palliation of symptoms. Late complications appeared reduced by hyperfractionated treatment delivery.
PURPOSE: The purpose of this study was to analyze the efficacy and acute and late toxicity of reirradiation for recurrent rectal cancer. METHODS AND MATERIALS: Fifty-two patients with recurrent rectal adenocarcinoma following previous pelvic RT underwent reirradiation. Median initial RT dose to the pelvis was 50.4 Gy. Median reirradiation dose was 30.6 Gy. Twenty-two patients received 1.2 Gy b.i.d., and 30 patients received 1.8-2.0 Gy daily. Total cumulative doses ranged from 66.6 to 104.9 Gy (median: 84.4 Gy). Forty-seven patients (90%) received concurrent 5-FU chemotherapy. Forty-four patients were followed until death, and the median follow-up time was 16 months. RESULTS: The RTOG Grade 3 acute toxicity rate was 31%. The RTOG Grade 3 and 4 late toxicity rates were 23 and 10%, respectively. On multivariate analysis, the only factor associated with reduced late toxicity was hyperfractionated delivery of reirradiation. Bleeding, pain, and mass effect were palliated completely in 100, 65, and 24% of instances, respectively, and the majority of responding patients were palliated until death. The overall median survival time from retreatment was 12 months. The 2- and 3-year overall actuarial survival rates were 25 and 14%, respectively. CONCLUSION: This unique institutional approach to recurrent rectal cancers resulted in excellent palliation of symptoms. Late complications appeared reduced by hyperfractionated treatment delivery.
Authors: Amar U Kishan; Justin C Voog; Jonathan Wiseman; Ryan R Cook; Marek Ancukiewicz; Percy Lee; David P Ryan; Jeffrey W Clark; David L Berger; James C Cusack; Jennifer Y Wo; Theodore S Hong Journal: Br J Radiol Date: 2017-06-14 Impact factor: 3.039
Authors: Jun Jie Wang; Hui Shu Yuan; Jin Na Li; Wei Juan Jiang; Yu Liang Jiang; Su Qing Tian Journal: Int J Colorectal Dis Date: 2008-12-16 Impact factor: 2.571
Authors: Cielito C Reyes-Gibby; Wenyaw Chan; James L Abbruzzese; Henry Q Xiong; Linus Ho; Douglas B Evans; Gauri Varadhachary; Samrat Bhat; Robert A Wolff; Christopher Crane Journal: J Pain Symptom Manage Date: 2007-05-21 Impact factor: 3.612
Authors: Waqar Haque; Christopher H Crane; Sunil Krishnan; Marc E Delclos; Milind Javle; Christopher R Garrett; Robert A Wolff; Prajnan Das Journal: Radiat Oncol Date: 2009-11-18 Impact factor: 3.481